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Despite mass drug administration programmes with praziquantel, the prevalence of
schistosomiasis remains high. A vaccine is urgently needed to control transmission of
this debilitating disease. As some promising schistosomiasis vaccine candidates are
moving through pre-clinical and clinical testing, we review the immunological challenges
that these vaccine candidates may encounter in transitioning through the clinical trial
phases in endemic settings. Prior exposure of the target population to schistosomes
and other infections may impact vaccine response and efficacy and therefore requires
considerable attention. Schistosomes are known for their potential to induce T-reg/IL-10
mediated immune suppression in populations which are chronically infected. Moreover,
endemicity of schistosomiasis is focal whereby target and trial populations may exhibit
several degrees of prior exposure as well as in utero exposure which may increase
heterogeneity of vaccine responses. The age dependent distribution of exposure and
development of acquired immunity, and general differences in the baseline immunological
profile, adds to the complexity of selecting suitable trial populations. Similarly, prior or
concurrent infections with other parasitic helminths, viral and bacterial infections, may
alter immunological responses. Consequently, treatment of co-infections may benefit
the immunogenicity of vaccines and may be considered despite logistical challenges.
On the other hand, viral infections leave a life-long immunological imprint on the human
host. Screening for serostatus may be needed to facilitate interpretation of vaccine
responses. Co-delivery of schistosome vaccines with PZQ is attractive from a perspective
of implementation but may complicate the immunogenicity of schistosomiasis vaccines.
Several studies have reported PZQ treatment to induce both transient and long-term
immuno-modulatory effects as a result of tegument destruction, worm killing and
subsequent exposure of worm antigens to the host immune system. These in turn
may augment or antagonize vaccine immunogenicity. Understanding the complex
immunological interactions between vaccine, co-infections or prior exposure is essential
in early stages of clinical development to facilitate phase 3 clinical trial design and
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implementation policies. Besides well-designed studies in different target populations
using schistosome candidate vaccines or other vaccines as models, controlled human
infections could also help identify markers of immune protection in populations with
different disease and immunological backgrounds.
Keywords: schistosomiasis, vaccine-candidate, praziquantel, co-infections, endemic, vaccine response,
co-administration, co-delivery
INTRODUCTION
Schistosomiasis is a poverty associated chronic disease caused
by parasitic trematodes of the genus Schistosoma (1). Over
190 million people globally are actively infected, of which
90% live in Africa (2) and over 200,000 deaths result from
schistosomiasis disease annually in Sub-Saharan Africa (SSA)
(1). The two main forms of African schistosomiasis, caused by
Schistosoma haematobium and S. mansoni parasites, affect the
urinary and gastro-intestinal tract, respectively. The intermediate
host, fresh water snails of the genus Bulinus and Biomphalaria
shed infective cercariae in water where they penetrate the skin
of the human host. Water-related livelihood activities, such as
fishing, thus drive transmission in resource limited settings with
poor hygiene and sanitary facilities (3). Following exposure,
schistosomula migrate through the blood stream and lungs
to the mesenteric and/or peri-vesical vessels intestinal venules
where they mature into female and male adult worms. Adult
worms mate and the female produces eggs that are released from
the intestinal or urinary tract to complete the cycle. Pathology
results mainly from accumulation of deposited eggs that induce
inflammatory responses, granuloma formation and fibrosis. This
results in strictures and calcification in the urinary tract due to S.
haematobium egg deposition, and liver fibrosis from S. mansoni
egg deposition in the Liver. Long term consequences include
hydronephrosis and kidney failure in the case of S. haematobium
infection, and hepatosplenomegaly and portal hypertension in
the case of S. mansoni infection, accounting for themorbidity and
mortality in schistosomiasis disease (4, 5).
In the last decade, the World Health Organization (WHO)
set an ambitious goal of controlling schistosomiasis by the
year 2020 and eliminating it as a public health burden by
2025. Initially, increasing coverage of mass drug administration
(MDA) of praziquantel (PZQ), the only drug currently used
for schistosomiasis treatment (6), was thought to be sufficient
to achieve this. Unfortunately, the increased coverage of MDA
decreases the intensity of infection and thus suffices as a tool
to alleviate schistosomiasis morbidity but does not prevent
re-infection. Consequently, prevalence can be restored in 6–
8 months after PZQ administration (7). As a result, control
programs rely on the repeated administration of PZQ, whilst
facing significant challenges with drug uptake, adherence and
sustainability. Hence, schistosomiasis remains a paramount
public health concern and economic burden in the resource
limited countries (6). Also, the full dependency on a single drug
poses a threat of drug resistance (7). This leaves vaccination
a key approach for the control and possible elimination
of schistosomiasis. An effective vaccine could contribute to
prevention and protection against re-infection. Consequently,
schistosomiasis has been ranked among the top ten diseases
for which a vaccine is urgently needed (8). The current overall
consensus on preferred product characteristics (PPC) for an
effective prophylactic vaccine is induction of 75% reduction in
worm burden in immunized individuals and egg excretion in
infected patients (9).
However, development of a novel schistosome vaccine faces
several scientific challenges due to the immune evasive nature
of adult schistosomes and schistosome-induced host immune-
modulation. Illustrated by the fact that no human anti-helminth
vaccines exists, the development of a schistosomiasis vaccine
is likely to be more complex as compared to the recent rapid
development of SARS-CoV-2 vaccines. Most importantly, the
multi-stage nature of schistosomes, transforming from cercariae
to Schistosomula, adult worms and ultimately eggs, involves
complex antigenic switches which are life-stage specific, but can
also be present across life stages. In addition, the induction of IgE
responses, associated risk of allergic reactions and the potential of
aggravating granulomas and fibrosis by egg-mediated responses
(10) makes schistosomiasis vaccine development complex.
Moreover, poly-parasitism and co-infections, a predominant
phenomenon in schistosomiasis endemic regions, mediate
cross-immune-regulation whereby one infection influences
susceptibility, intensity and immune responses to the other
(11). In addition, there is inadequate understanding of how
past and existing schistosome infections, repeated exposure,
poly-parasitism and prior treatment explicitly structure the
immune system in individuals, within and between the different
populations. These factors are likely to increase heterogeneity in
vaccine responses. Further, the need to implement vaccines in the
context of the current MDA control programmes necessitates an
integrated approach to praziquantel and vaccine administration
(9). However, co-administration of vaccines and praziquantel
presents divergent immunological dynamics that have to be
considered. Here, we review the immunological challenges for
schistosome vaccine development and testing in endemic settings
and provide perspectives of how this scientific priority area can
be accelerated.
The Progress Toward a Schistosome
Vaccine
The initial approach in the quest for a schistosomiasis vaccine
involved vaccinating mice with live attenuated cercariae and
schistosomula followed by a challenge infection to assess
protectivity. These studies demonstrated that 60–70% protection
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was achievable with a single immunization and could be boosted
up to over 90% with subsequent immunisations (12, 13).
This approach was similarly efficacious in baboons eliciting
protection of over 50% to schistosome larvae challenge and 89%
reduction in worm burden, upon immunization with gamma-
irradiated cercariae (14). However, despite induction of close to
100% protection (13), this approach is difficult to translate to
humans (15).
Nevertheless, these studies provided a strong indication for
schistosome vaccine discovery, and knowledge on induction
of protective immunity. Acquired immunity was found to be
mainly associated with a Th1 type IFN-γ and TNFα pulmonary
inflammatory and antibody response, IL-4, IL-5, and eosinophils
are of negligible importance meanwhile, IL-10 and IgG4 negates
protection and are associated with re-infection (9, 13, 14).
Conclusively, these studies denoted that excessive induction of
either Th2 or Th1 could lead to damaging pathology and thus,
induction a balanced Th1 and Th2 response is fundamental for
achieving optimal protection (15).
Utilizing advancements in technology, vaccine development
has, in the recent past, shifted focus from irradiated parasite
vaccines to specific antigen molecules. Nonetheless, vaccination
with irradiated S. mansoni cercarie has contributed to the
identification of five such molecules including the Sh28GST and
the Sm14 which have proceeded to human clinical trials (12, 15)
as discussed below and further reviewed by Molehin (9) and
McManus et al. (15)
S. haematobium 28-kD Glutathione S-Transferase
(rSh28GST)
This glutathione S-transferase (GST) antigen is a worm
detoxification enzyme which is important in preventing parasite
oxidative stress (16). Ultrastructural localization of the 28GST
show a dense cytosolic, as well as genital, tegumental surface
and parenchyma distribution in the schistosome parasite
(17). Thus, the 28GST is closely associated with the parasites’
muscular organs and anti-28GST specific antibodies mediate
Antibody-Dependent-Cellular-Cytoxicity (ADCC) and also
inhibit transferase activity of the enzyme interfering with muscle
function and ultimately in reduced worm fecundity (18, 19).
Rodent studies demonstrate that 28-kDa fraction of GST
(Sh28GSGT) elicits an antibody response which is capable of
inhibiting the native GST enzymes, conferring between 40
and 70% protection in rats, mice, hamsters and baboons (20).
Experimental infection studies in non-human primate models
revealed an anti-fecundity effect with significant reduction in
tissue egg load and fecal egg excretion despite a lack of effect on
adult worm burden (21).
The phase I trial reported safety and tolerability of the r28GST
in Alum formulation in human subjects. The immunological
read-abouts demonstrated that 28GST vaccine candidate is
highly immunogenic, inducing high levels of specific IgG1,
IgG2, IgG3 antibodies. A strong Th2 cytokine response was
also observed, typically IL-5 and IL-13 cytokines (22). Though
findings from the phase II trial are yet to be published, the
phase III trial, a randomized parallel-group double-blinded trial
in school children in endemic Senegal, reported a good tolerance
of the vaccine with induction of long lasting vaccine specific
response. High titres of IgG1, IgG2, and IgG were induced
in the vaccine group. However, this vaccine candidate did not
show sufficient protection and this was attributed to failure to
induce the desired specific-IgG3. The investigators of this trial
also attribute this to interreference by the praziquantel treatment
that was administered after the first vaccine dose and before the
booster dose (18). Post vaccination treatment with PZQ, which
coincides with elaboration of immune response to a vaccine, has
been shown to interfere with cytokine response (18, 23, 24).
S. mansoni 14-kDA Fatty Acid Binding Protein (Sm14)
Sm14 is one of the fatty acid binding (FABP) proteins that play a
crucial role in the uptake, transport and compartmentalization
of host-derived sterols by schistosomes (25). Sm-14 protein
enzymes are localized in the cytosol and in tissues adjoining the
interfaces of parasite/host contact such as the basal lamella of the
worm tegument and muscles layers to enable acquisition of lipids
from the host (26). They are also found in the gut epithelium
for lipid transportation and utilization throughout the parasite.
Sm14-specific antibodies bind to tubercles on the parasite’s dorsal
surface and interfere with uptake of lipids essential for parasite
survival as well as mediate ADCC (27).
In rodent studies, Vaccination with the rSm14 induced up
to 66 and 89% protection, of Swiss mice and New Zealand
white rabbits with, respectively (28). Sera from immunized mice
showed generally high reactivity and significant level of rSm14-
specific IgM, although IgG and IgA titres were low (29).
In the phase I trial, the Sm14/GLA-SE formulation was safe,
highly tolerable and immunogenic in adult male human subjects.
It induced a strong CD4+ T cell response producing single
Th1 cytokines, particularly the TNF and IL-2. Also, high titres
of Sm14-specific IgG, IgG1, and IgG3 antibodies were elicited
in vaccinated individuals (27, 30). The Sm14 vaccine has now
advanced to a phase IIb trial to be conducted in school children
in the endemic Senegal river basin region (25) (NCT03799510).
S. mansoni Tetraspanin-2 (Sm-TSP-2)
Sm-tetraspanin is a member of a four-domain-structured
tetraspanin surfacemembrane protein linked by two extracellular
loops and made of two types, TSP-1 and TSP2 (31). The main
vaccine antigen in the Sm-TSP candidate vaccine is comprised
of the extracellular loop and the TSP-2 type. The TSP-2 antigen
was found to be more strongly recognized by IgG1 and IgG3
antibodies in the sera of naturally immune populations, unlike
TSP-1 (32). The TSP-2 is a readily immune-accessible antigen
on the surface of newly transformed schistosomula and a critical
tegument protein for nutrient acquisition, waste excretion and
immune evasion. Anti-TSP-2 antibodies interfere with these
parasite survival mechanisms and elicit a protective immunity
against infection in a vaccinated host (32).
Immunization with Sm-TSP-2 result in 57% and 62%
reduction in worm and liver egg burden, respectively, and
69% reduction in fecal egg count, in rodent models (32). An
increased production of Sm-TSP-2 specific antibodies and IL-4,
IL-10 cytokines by spleen cells is also observed in immunized
animals (33).
Frontiers in Immunology | www.frontiersin.org 3 March 2021 | Volume 12 | Article 635985
Driciru et al. Immunological Considerations for Schistosoma-Vaccine Development
Phase Ia and phase Ib trials of the Sm-TSP-2/Alhydrogel
(Sm-TSP-2/AI) have both been initiated to investigate safety
and immunogenicity of this vaccine candidate in human subject
(NCT03910972). Phase I trial of the Sm-TSP/Alhydrogel with
or without glucopyranosyl lipid A (GLA-AF) formulation in
non-endemic setting show the vaccine is safe and tolerable
among Sm-naïve individuals (34). The “Sm-TSP/Al with GLA-
AF” formulation elicited higher sero-response than the “Sm-
TSP/Al without GLA-AF” and placebo, with a dose-response
relationship exhibited by Sm-TSP/Al with GLA-AF (34).
S. mansoni Sm-p80/GLA-SE
Sm-p80 is the large subunit of calpain, a calcium activated
neutral tegument protease, which is located in and on the
surface epithelial syncytium and mediates tegument biogenesis
for host immune evasion. Sm-p80 is a highly immuno-dominant
membrane antigen with no cross-reactivity with vertebrate
calpains (35).
Amultitude of studies performed in vitro, in rodents and non-
human primates over the past 23 years have demonstrated that
Sm-p80 is a very promising vaccine candidate with prophylactic,
therapeutic, anti-pathology and transmission blocking efficacies
(36). Significant reduction in adult worm burden, tissue egg
load and fecal egg excretion following Sm-p80 vaccination has
been demonstrated, whereas potentially allergic IgE responses
have not been registered (37). Sm-p80 immunization elicits
significant complement-dependent killing of schistosomula (36).
Administration of PZQ preceding Sm-p80 vaccination is proven
to profoundly reduce tissue egg retention and hatching in non-
human primates (38, 39). Following the desirable responses
and results from rodent and non-human primate studies, Sm-
p80/GLA-SE has now been approved for phase I clinical trial (9).
As schistosomiasis candidate vaccines are progressing from
phase I studies to testing in the target populations in several
endemic settings, the distinctive disease exposure, co-infections
and transmission settings that uniquely shape the immunological
profiles may result in heterogeneity in vaccine responses. Hence,
in addition to the existing logistical, accessibility and resource-
limitation challenges, the immunological complexity presents
exceptional challenges to vaccine development and testing in
schistosomiasis endemic regions.
Prior/Current Infection With Schistosomes
and Antigen Sensitization
Generally, prophylactic vaccines are given to naïve individuals
but for potential Schistosoma vaccines, this may be challenging
as sensitization to Schistosoma antigens is likely to occur early
in life or even in utero in endemic settings (40). Prior exposure
to antigens included in a vaccine may enhance or suppress
vaccine responses.
At birth, the offspring of Schistosoma infected mothers already
show signs of B and T-cell sensitization to parasite antigens
(41), with detectable schistosome-specific antibodies (including
IgE), T cell responses in cord blood, and schistosome antigens
in the urine of new-borns (40, 42). Even with zero egg counts,
antibodies in infant serum recognize some worm antigens (43,
44). Following childhood exposure, infection peaks in 6–15
years old children (19) and can be as high as 90% in <12
years olds (45, 46). The peak and dispersion in worm burden
gradually declines with age (46), which could be a reflection of
reduced exposure or, in high exposure settings, the induction
of naturally acquired immunity. Naturally acquired immunity
is characterized by a broadening of antibody repertoire and a
switch from predominantly egg-specific IgG1, IgG2, and IgM
antibodies in infancy to a protective larval and adult worm-
specific IgE antibodies toward adulthood and increasing duration
of exposure (43, 47–49). IgE response, elicited after repeated
exposure and or PZQ treatment is associated with protection
(though not exclusively) in endemic populations (10). Natural
or PZQ-driven death of adult worms releases parasite antigens
from migrating larvae and this induces IgE response (50)
which mediates antibody-dependent-cellular-cytoxicity (ADCC)
killing of more parasites (31). Although not useful in vaccine
development due to the potential to induce hypersensitivity
(10), an IgE mediated protective immunity is subsequently
developed in individuals, over many cycles of infection and or
treatment (51).
This raises the question of how pre-exposure and pre-
existing immunity influences vaccine responses. Depending
on the vaccine antigen and the pathogen, the effect of pre-
exposure may vary. For instance, reduced cytokine responses to
Bacillus Calmette-Guérin (BCG) vaccination have been linked
to previous exposure to other mycobacteria, but studies with
hepatitis B vaccines show conflicting results with increased
antibody responses after pre-exposure in one study, and lower
in another study (52). For schistosome antigens, there is no
evidence so far that pre-existing exposure to vaccine antigens
negatively impacts schistosomiasis vaccine responses. In the
rSh28GST Phase 3 study, pre-existing immune responses to the
28GST antigen were observed in children aged 6–7, but there
was no evidence of pre-existing anti-28GST responses negatively
impacting vaccine immune responses (18). In addition, in
studies with recombinant Sm14, high levels of the Th1 cytokines
IFN-γ, and TNF-α could be observed despite a history of
chronic exposure (53). This is in agreement with animal
experiments which showed that successful immunization could
be achieved in previously infected and cured baboons (39). As
such, current data suggest that schistosome vaccines may retain
immunogenicity despite prior exposure. However, the impact
of prior exposure on vaccine responses may differ for each
antigen and should therefore be carefully assessed in early-stage
trials to avoid reduced efficacy results in phase three trials or
implementation settings.
Population Differences in Immune Profile
Affecting Vaccine Responses
Differences in the baseline immune profiles between populations
are known to affect both quantitative and qualitative response
to vaccines (54). Since novel vaccine candidates are typically
assessed for phase I safety trials in a non-endemic European
population, it should be borne in mind that generally lower
vaccine responses are found in African populations (55–58).
The immune profile of African cohorts, in contrast to
Caucasian populations, typically contains more exhausted and
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activated NK cells, differentiated T and B cells and pro-
inflammatory monocytes (56, 59). This immune profile was
associated with a low vaccine-specific neutralizing antibody
response and a poor efficacy to the yellow fever vaccine 17D (YF-
17D) as compared to a Swiss cohort (56). BCG vaccination in
African adults and children elicited low IFN-γ response and a
mixed cytokine profile in a setting where BCG efficacy is low,
but a predominant Th1 cytokine profile in the United Kingdom
where BCG efficacy is 50–80% (55, 57, 60). Also, African infants
did not show increase in the magnitude of T cell response to
the MVA85A TB candidate vaccine unlike their UK counterparts
(61). Furthermore, the HIV-adenovirus-vectored (Ad26.EnvA.01
and Ad35-EnvA) candidate vaccines induced better efficacy and
greater T cell responses in an American cohort compared to
South and East African subjects (58). These findings suggest
that the baseline immune profile of African populations may
interfere with adequate vaccine responses and this effect is
especially important for the viral vectored and live vaccines such
as the MVA85A and Ad26/35-EnvA, and BCG and YF-17D,
respectively (55, 57, 61).
Genetic difference between populations could contribute to
heterogeneity in vaccine responses. Vaccine immune responses
are regulated by multiple gene complexes and networks which
may be subject to genetic variations such as inherent cytokine
and HLA gene polymorphisms (62, 63) and thus, difference
in immune phenotype and functional response. For instance,
Indonesians were shown to express the unique CD11c+
IL-10 producing B cell subset as compared to Europeans
(64), depicting a possible genetic disparity. In a malaria
endemic region in Mali, both adults and children exhibited an
atypical FcRL4+ expressing memory B cell population unlike
their American counterparts (65). Furthermore, volunteers
of Congolese origin expressed a distinctly high number
of STAT6 and IL10RA regulatory gene polymorphisms, a
genetic evidence that explains the predominantly asymptomatic-
uncomplicatedmalaria infectionmanifestation in this population
(66). Differences in response to vaccines such as the measles
vaccine have also been attributed to genetic polymorphisms in
the CD46 and SLAM gene receptor (67).
However, there is increasing evidence suggesting that inter-
population differences in immunological profiles are driven by
non-inheritable environmental factors such as prior and current
infection status which may typically be vastly different between
rural vs. urban living (59, 68, 69). For example, rural African
populations express a superior immune activated state, larger
memory pool and Th2 polarization as compared to urban
Africans (64) and Indonesians from a non-endemic urban setting
showed a similar immune profile to European subjects yet
markedly differed from Indonesians from an endemic rural area
(59). More so, a type 2 immune profile comprising of Th2
cells, IL-4, IL-5, and IL-13 cytokines is typical of schistosomiasis
high-exposure endemic populations (70). Subjects from the
endemic setting exhibited a high frequency of CD161+Th2 cells,
CCR6-KLGR1+ ILC2, CTLA+ T regs and IL-10+ CD11c+ B
cells (64). Subjects from a rural setting in Uganda showed a
decreased specific cytokine and antibody response to tetanus
toxoid andMtb purified derived protein (PPD) compared to their
urban counterparts which persisted after adjusting for helminth
infection (71).
Therefore, early phase clinical trials should preferably be
conducted in target populations to ensure no gaps in translation
at a later stage. In addition, booster regimens, potent adjuvants
and higher antigen dose can be considered particularly for
endemic populations such as in SSA where low vaccine response
and efficacy is predominant.
Co-infections
Besides prior and current schistosome exposure, schistosomiasis
endemic populations are also highly diverse with regards to
exposure to other infections. Chronic viral infections and
poly-parasitism in schistosome endemic populations constantly
expose the host immune system to a complex array of antigens
and epitopes causing antigenic competition and immune
sensitization (72). In addition, parasitic infections such as
lymphatic filariasis, onchocerciasis and leishmaniasis often occur
in schistosome endemic areas. This trains and pre-sets the
immune phenotype and functionality, potentially distorting the
host response to, vaccine candidates.
Noteworthy, in this review we focus on the concomitant
parasitic (malaria and soil-transmitted helminths) and viral
(Cytomegalovirus) infections which are highly prevalent among
schistosomiasis endemic populations in the low and middle
income countries (LMIC) (73, 74). Parasitic co-infections are
of particular importance due to the significant negative impact
on immunization especially among parasite endemic populations
which are the target for schistosomiasis vaccine trials (73).
Malaria Co-infection
Malaria and schistosomiasis are both parasitic diseases that
share co-endemicity, and cause significant morbidity and
damaging socio-economic effects (75). With schistosomiasis only
ranking second to malaria, these two parasitic diseases exhibit
an overlapping geographical distribution pattern and a high
prevalence of co-infection across the tropics and sub tropics
(75). The prevalence of malaria is highest in children (76)
and is mainly caused by Plasmodium falciparum. In fishing
communities, which are a target population for schistosomiasis
vaccine trials due to the high schistosomiasis transmission and
intense exposure, the risk and prevalence of malaria co-infection
is very high (77). The presence of breeding sites in the lake
environment such as stagnant pools of water on the shores and
unused old boats, fish bait mines and finger-ponds traps which
sustain a heavy vector population in these communities (78).
Also, fishing activities such as nocturnal fishing promote outdoor
transmission as well as the temporary makeshift housing that is
porous to the malaria vector (79).
Primarymalaria infection induces CD4+ T cell differentiation
into CXCR+ T follicular (Tfh) cells to provide B cell help
and the highly proliferative Vγ9+Vδ2+ T cells produce high
levels of IFN-γ (80). Production of pro-inflammatory cytokines
and chemokines such as IL-1β, IL-6, IL-8, IL-12, IFN-γ, and
TNF induce fever and other signs and symptoms in previously
unexposed individuals resulting in severe and fatal malaria
(81). Increased TNF levels are associated with severe and
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cerebral malaria infection although sustained high levels result
in reduction in parasitemia and improvement of fever (82,
83). However, this Plasmodium-induced inflammatory response
also controls parasite replication and resolves infection through
IFN-γ and TNF mediated killing of parasite (84). Meanwhile,
acute uncomplicated infection activates the less functional
CXCR3+PD1+ Tfh cells which enhances production of IL-
21 and pro-inflammatory cytokines (85). P. falciparum malaria
infection additionally prompts dysregulation of B- and CD4+T
cell function subsequently, causing significant and rapid loss of
Pf -antigen-specific antibodies (85, 86). Asymptomatic malaria
is an important consideration for clinical trials since it is
the most common form among adults, the ideal early-phase
trial subjects in endemic settings. Asymptomatic malaria is
characterized by increased Treg numbers, IL-10 and TGF-
β production, and dampened TNF, IFN-γ pro-inflammatory
response characterizes (87). P. falciparum-induced upregulation
of IL-10 production by CD4+Foxp3- Th1 cells rather than T
regs, is usually sustained in persistent asymptomatic infection
(88). Malaria infection additionally affects B cell phenotype
and function. In repeated malaria infections and persistent
asymptomatic parasitemia, accumulation of atypical memory
B cells, a hyporesponsive anergic B cell subset expressing
several inhibitory receptors, is seen (89, 90). Expansion of
atypical memory B cells associated with clinical immunity
following acute malaria has also been reported (91). This
immunological memory may have implications on vaccine
response given that it may distort the balance between
antibody affinity maturation and B cell clonal selection following
vaccination (90, 92).
Acute malaria has been reported to lower response to
tetanus and diphtheria toxoids, meningococcal polysaccharide,
Salmonella and Haemophilus influenza conjugate and whole
vaccines (93–95). Fever associated with malaria infection
contributes to a diminishing response to Haemophilus influenza
vaccine (94). More so, asymptomatic parasitemia in malaria
infection is associated with a decreased response to the newer
acellular pertussis and meningococcal vaccine (85). Similarly,
malaria infection during pregnancy and in infancy decreases
antibody response to infant measles vaccination (96). These
findings suggest and support treatment of malaria before
vaccination is necessary to alleviate the antagonizing immune
effects. Indeed, there is evidence that the response to some
vaccines (such as the tetanus vaccine) improve following
malaria chemoprophylaxis (93). However, pre-treatment does
not improve response to or even impair immunogenicity of some
vaccines such as the measles vaccine (93).
In co-endemic populations, it seems reasonable to test
and treat malaria infections prior to vaccine administration.
However, the added complexity of malaria pre-treatment in
implementation settings makes it imperative to investigate the
effect of asymptomatic malaria on vaccine response before phase
3 trials are performed. In addition, the optimal timing of malaria
chemotherapy with regards to vaccine administration will need
to be considered in order to optimize effects in different malaria
transmission settings.
Soil-Transmitted Helminths (STHs) Co-infection
Soil-transmitted helminths (STHs) and schistosomiasis are
predominantly co-endemic (97). It is estimated that one-third
of the population in SSA is infected with one or more STH
(98). This prevalence is driven by the overlapping poverty-
related conditions of poor environmental hygiene, improper
waste disposal, in adequate water supply and pollution of
water bodies (99). The common STHs are the round worm
(Ascaris lumbricoides), hookworms (Necator americanus and
Anyclostoma duodenale), whipworm (Trichuris tichuria), and
Strongloides stercoralis (97). However, hookworm and A.
lumbroicoides infections seem the most prevalent of helminth
co-infections in schistosomiasis infected individuals in many
endemic areas (100, 101). Young children and males are more
prone to the infections due to poor hand hygiene practices
and active behavior that exposes them to contaminated soils
and water (99). This high prevalence among adult males is an
indication of a greater likelihood of existing or past infection, a
caution for possible distortion of host immune response to other
infections and vaccines. And also a challenge to the selection of
trial subjects in co-endemic settings.
STH infection impairs development of protective immunity
possibly as a result of the potent chronic suppression of the
Th1 response required for protection against pathogens (72).
STH infections typically induce a type-2 biased immune response
(102). Therefore, elevated levels of IL-4, IL-5, IL-13, IgE in
addition to general modulation of both innate and adaptive
immune systems can be expected in STH co-infection (102).
Chronic STH infection not only induces potent local but also
systemic down regulation of the immune system. For instance,
human subjects challenged with N. americanus exhibit a strong
local and systemic Th2 and T reg response with high levels of
IL-10 and TGF-β production (103). In chronic STH infection,
it is the increased functional activity of the FOXP3+ Tregs
which mediates immune suppression, rather than an increased
frequency in chronically infected human hosts (104).
This potentially affects not only susceptibility and outcome
of concurrent infections but response and efficacy of vaccine
candidates (105). Studies in both human and mouse models
report poor immunogenicity of the BCG vaccine in STH
infected subjects (106). Decreased T cell proliferative response
to BCG in helminth infected children was found to result
from an enhanced T reg functionality and subsequent immune
suppression during chronic infection (104). Besides, the immune
profile to recombinant cholera toxin B subunit following live
oral cholera CVD 103-HgR vaccination in helminth infected
subjects is characterized by low IFN-γ, IL-2, and IL-12 (107),
indicating a suppressed immune response. Particularly, existing
Onchocerca infection significantly decreases immune response
to tetanus vaccination compared to subjects without helminth
infection (108). On the other hand, STH infections do not alter
IgG antibody responses to previously administered measles and
tetanus vaccines (109). Hence, with the changing lifestyle, better
hygiene practices and anti-helminth treatment, there is a gradual
reduction in helminth infections in many LMIC and one would
expect better vaccine responses. This has indeed been shown in
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animal studies and in humans, findings from number of studies
do support that treatment of STHs alleviate immune suppression
and improve vaccine responses as reviewed elsewhere (110).
Helminth treatment, usually by oral administration of
benzimidazoles i.e., albendazole (400 mg/kg) and mebendazole
(500mg), before vaccination may be beneficial for boosting
vaccine responses. Deworming of subjects with Albendazole
before BCG vaccination was reported to enhance BCG vaccine-
specific response (111). A similar boosting effect on oral cholera
vaccine among helminth infected subjects is exhibited (112).
This is possibly due to alleviation of the helminth-induced
immune suppression by anti-helminth treatment. Albendazole
deworming is associated with enhanced pro-inflammatory
responses and down regulation of inhibitory receptor expression
CTLA, by the immune suppressive Tregs (113). However, one
study did not find any significant effect of albendazole treatment
on influenza vaccine response, despite the increased total IgA
titres in the anti-helminth treated group (114).
Nevertheless, testing and treating of helminth infections
may be beneficial in phase I schistosomiasis vaccine trials.
Treatment before vaccination would alleviate the immune
suppression induced by helminth infection prior to vaccine
administration and thus, enable better response to vaccines.
Meanwhile, treatment around time of vaccine administration
possibly drives antigenic unmasking to expose more antigens
for host immune recognition. However, antigenic unmasking,
following PZQ treatment of intense pre-existing infection which
results in release of worm antigens in excess of vaccine antigen,
poses a risk of antigenic competition. This may result in poor
and or non-specific immune response following PZQ treatment
and vaccination. In this case, intensity of pre-existing infection
should be taken into consideration. It should be noted that the
duration and intensity of anti-helminth treatment itself does have
a differential effect on B and T cell response (115). Therefore,
not only the effect of STH infections but also their treatment on
vaccine response and efficacy should be investigated in late-phase
trials in endemic settings.
Human Cytomegalovirus (CMV) Co-infection
This double stranded DNA and enveloped virus belonging to the
Beta-herpesvirinae infects between 40 and 100% of adults, varying
in prevalence between populations (116). Approximately 90% of
the infection incidence occurs in the LMIC of Africa, Asia and
South America where up to 60% of the young adults and 90% of
elderly adults are sero-positive (117–119).
Besides the high prevalence, the induced immune modulation
and establishment of a periodically re-activated life-long latent
infection marks CMV a very important viral infection (120,
121). CMV infection typically distorts the T cell repertoire and
overall phenotype by inducing a rapid differentiation and clonal
expansion of CMV-specific CD8+ T cells. This T cell subset
can constitute up to 20% of the T cell repertoire, especially in
older adults, but is not functional in controlling the infection
(122). Meanwhile, the CMV-specific CD4+T cells increasingly
produce IFN-γ, and MIP-1β that mediate re-activation of other
latent infections in the host such as Tuberculosis (123). Chronic
CMV infection thus causes a continuous accumulation of highly
differentiated effector memory T cells. Besides, expression of
co-stimulatory receptors in these T cells is inhibited, together
resulting in a phenomenon known as “memory inflation” (124,
125), whilst at the same time depleting the naïve T cell pool (126).
Despite the universal host immune phenotype, the negative
effect of CMV infection on vaccine responses is most pronounced
in the elderly (120). CMV sero-positive elderly adults have been
reported to exhibit a decreased response to Influenza vaccine
(127, 128). A defective CD8+pSTAT1 and pSTAT3 pathway,
expanding senescent CD57+KLG1+ T cell repertoire and the
increasing TNF-α and IL-6 levels with infection duration, reduces
cytokine responsiveness of vaccine-induced T-cells (120, 128,
129). Findings in younger CMV infected adults are conflicting.
An enhanced response, characterized by high levels of circulating
Th1 and Th2 cytokines to Influenza vaccine is seen (127), possibly
due to the cross-reactive CMV-specific CD8+ T-cell epitopes
(130). Meanwhile, response to Ebola candidate vaccines, ChAd3
and MVA, is impaired (120).
Given that CMV establishes a life-long infection that cannot
be cleared or treated, the attention for vaccine trial design
and implementation should rather be focused around different
age of target populations. Phase I trials may consider testing
and exclusion of CMV sero-positive subjects, especially in
CMV low and moderate prevalence areas, for any vaccine
targeting young children or infants. However, this may not be
possible in populations where CMV infection is prevalent and
almost universal, even among children. For late-phase trials,
inclusion of CMV sero-negative vs. sero-positive subjects, could
help decipher possible interaction between CMV and vaccine
responses. Alternatively, general understanding of the possible
effect of CMV could first be investigated through fundamental
studies and then regimens such as booster doses for the sero-
positive subjects in late phase trials can be considered and
tailored accordingly.
Other Co-infections
Prevalent co-infections with obvious immune-modulation and
even immune incompetence induction are HIV and TB.
HIV/AIDS, a life-long viral infection with no cure presently
and the cause of profound immune-incompetence, is a prevalent
viral infection in SSA and other developing regions of the world
(131). Over 20 million people are infected in South and Eastern
Africa alone (132). HIV establishes a preferential infection and
depletion of CD4+ T cells, increases T cell activation, exhaustion
and death, impairs antigen presentation, CD4+ and CD8+ T
cell functionality (131, 133). This results in very low CD4+ T
cell count (below the 500 cells/mm3 lower limit), severe immune
impairment, poor vaccine response as well as rapid vaccine
induced decline (133, 134).
Combination anti-retroviral therapy facilitates immune
reconstitution and viral load suppression, despite persistence of
the virus in latent reservoirs (133), suggesting a near-optimal
immune response can be expected. Indeed improved vaccine
response and reduced risk of infection following Influenza,
PPV23 and PCV pneumococcal vaccinations has been reported
in patients on cART (135–137). Nevertheless, immune responses
in HIV infected patients may be lower, or wane off quicker,
Frontiers in Immunology | www.frontiersin.org 7 March 2021 | Volume 12 | Article 635985
Driciru et al. Immunological Considerations for Schistosoma-Vaccine Development
despite cART therapy as has been demonstrated in trials with
hepatitis B, Influenza, experimental TB and BCG vaccination
both in adults and children (138–143).
Despite the potential public health importance of vaccination
in HIV infected patients given their increased susceptibility
to vaccine-preventable diseases (144), they are often excluded
from vaccine trials because of safety concerns and unfavorable
benefit/risk profiles (145, 146). For example, the unfavorable
benefit/risk profile of BCG vaccination in HIV infected has to
led its constant contraindication (146–148). Therefore, testing
for HIV, exclusion of sero-positives from trials and referral for
cART treatment, is paramount for safety. However, given the
high percentage of HIV positive individuals in some areas and the
increased use of cART and non-viable vaccines, these populations
should be included at a later stage clinical testing of the vaccine to
expedite roll-out in these populations after potential registration.
Tuberculosis is another prevalent co-infection among
schistosomiasis endemic populations in LMICs affecting over
10 million people and causing significant immune-modulatory
impact on infected hosts (132). In active TB infection, levels of
IFN-γ, IL-1β, IL-18, are severely decreased and Treg numbers
rise thus immune suppression ensues in the infected host.
Consequently, a high FOXP3, TGF-β, and IL-4 and low IFN-γ,
expression in active TB patients is associated with poor response
to BCG vaccination (149, 150). However, an increased antibody
response to several unrelated antigens such as measles and
tetanus toxoid in active TB patients has also been reported (151).
Similar to HIV infection, active TB is a factor for vaccination
deferral due to safety reasons. Nevertheless, further studies
within and or outside vaccine trial studies may be important to
ensure no interaction occurs between latent TB infection and
schistosomiasis candidate vaccine response and efficacy.
The current COVID-19 pandemic has led to over 1.9
million deaths globally (152) inducing serious, potentially
long-term immunological perturbations in the infected host
that may influence vaccine responses in the same individual.
The severity of the COVID-19 disease is associated with the
hyper-inflammatory response, “cytokine storm,” especially in
the presence of co-morbidities such as diabetes and obesity
which are characterized by elevated levels of pro-inflammatory
IFN-y,IL-1B,IL-12,IL-6,IL-27, and TNF cytokines (153). It has
been suggested that the Th2 biased, T-reg, IL-10 mediated
immune hyporesponsive and controlled inflammatory state in
schistosomiasis infection (154) could counteract the damaging
effects of COVID-19 disease and limit morbi-mortality (155).
This theory could explain the relatively low severity and fatality
rates of the COVID-19 in the helminth-endemic Africa (156,
157). However, there is currently no evidence to prove this
COVID-19 and helminths interaction.
PZQ Co-administration
PZQ, an acylated isoquionoline-pyrazine derivative, is the main
drug used in the treatment of schistosomiasis and the basis of
community-based mass drug administration (MDA) programs
for the last 30 years (51, 158). PZQ, administered orally at dosages
of 40–60mg.kg−1, is efficacious against adult worms with low
toxicity and safe, even in pre-school age children and in third
trimester pregnancy (159, 160). Although the mechanism of
action of PZQ is not entirely understood, it is widely accepted
that it disrupts the worm calcium homeostasis leading to worm
muscle contraction and paralysis (158, 161, 162). The ensuing
PZQ-induced tegument vacuolation and blebbing exposes the
worm surface antigens, previously concealed in the intact live
parasite to host’s immune system (Figure 1) (162). In vivo
studies show extensive structural changes in the tegument, sub-
tegumental and gastro-dermal musculature, causing leakage of
tegumental cytoplasm from live worm in the first 15min of
PZQ treatment (163). Rodent studies have shown that PZQ-
induced tegument disruption leads to exposure of a previously
concealed native GST enzyme 90 minutes post PZQ treatment
(164). Also in humans, drastic increases in cytokine release after
PZQ treatment suggests that chemotherapy results into a pulse
release of antigens (165) (Figure 1). This suggests that PZQ
not only exposes tegument antigens but also cytosolic antigens
and enzymes essential for parasite survival to the host immune
system, enhancing further tegument damage and parasite killing.
As a consequence of antigenic unmasking, PZQ treatment
may enhance antigen recognition of antigen-protein-isoforms
that would otherwise be hidden (166). Post-treatment serum
samples from S. haematobium patients have been shown to
recognize a greater number of proteins compared to pre-
treatment sera. More so, some proteins and their isoforms
are recognized only in post-treatment serum samples (166).
Noteworthy, the proteins that show enhanced recognition post
treatment are generally those that are associated with parasite
musculature and glycolytic metabolism (167), consistent with
the disruptive mechanism of action of PZQ. This enhanced
antigen recognition permits better neutralization by antibodies
raised by vaccination (164, 168). Increased antigen recognition
consequently enhances affinity maturation of immunoglobulin
responses such as worm specific IgE. For instance, high IgE titres
following PZQ chemotherapy ensues from directed IgG affinity
maturation induced by PZQ (167), an effect which may also be
conferred to co-administered vaccines and moreover lead to a
more sustained antibody response following vaccination (164).
Besides, antibody titres IgG1, IgG2, IgG4, IgM against worm
antigens and IgG2, IgE to egg antigens are boosted following PZQ
administration (169).
On the other hand, antigenic competition as a result of PZQ-
induced parasite killing could suppress response to the single
vaccine antigens. This is because PZQ-induced parasite killing
avails large amounts and or a variety of crude worm antigens
into the blood stream, in excess of vaccine antigen load. This can
potentially overshadow vaccine response or elicit non-specific or
undesirable immune response (170). In the phase 3 human trials
of the rSh28GST vaccine candidate, PZQwas administered before
and after the initial vaccination as well as just before and after
the booster vaccination. No significant delay in schistosomiasis
recurrence was seen in the vaccine group compared to the control
group despite vaccine induced immunity (18). Although this
may be attributed mainly to the failure to induce the desired
IgG3 and IgA protective antibody response but rather IgG4
responses, interference by the repeated PZQ treatment was also
suggested to have, partly, contributed to the observed results (18).
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TABLE 1 | Summary of the immunological considerations for schistosome vaccine development.
1. Prior/Current
schistosome exposure
Immune-Modulation Key references Vaccine response Key references
a) In utero exposure
b) Early childhood exposure
c) Age-linked cumulative
exposure
B and T cell sensitization
Specific cord blood IgG, IgE
↑ IgG2 and IgM
↓ IgE
↑ Adult worm specific-IgE, IgM
↑ Antigen recognition








↓ BCG, Pf Sporozoite Vaccine







2. Difference in baseline
immune-profile/micro-
environment
Activated immune micro-environment in
African cohort
↑ Exhausted/activated NK cells
↑ Differentiated B and T cells
Pro-inflammatory monocytes
↑ Genetic differences; cytokine and HLA
gene polymorphisms
CD11c+ IL-10+ B cell expression in
Indonesians
Atypical FcRL4+ memory B cell in
Malian subjects
High STAT6 and IL10RA gene
polymorphism among Congolese
subjects
↑ Activated, memory pool Th2







↓ Yellow fever, HIV, BCG, MVA85A TB
vaccines in African cohorts
↓ HIV Ad26.EnvA.01 and Ad35-EnvA
candidate vaccines in African cohort
Measles vaccine heterogeneity due to
CD46 and SLAM gene polymorphism

















↑ IL-1β, IL-6, IL-8, IL-12, IFN-γ, TNF
Asymptomatic malaria
↑ IL-10, TGF-β, CD4+Foxp3-
Th1 cells, Tregs
↑ TNF, IFN-γ
Repeated and persistent infection







pertussis and meningococcal vaccines
↑ Measles vaccine upon malaria treatment









↑ CMV-specific CD8+ T cells
↑ IFN-γ and MIP-1β production
Memory “Inflation”
↓ T cell co-stimulatory receptor
expression




↓ Influenza vaccine in older adults
↑ Influenza vaccine in young adults





c) Soil trans-mitted Helminth
(STHs)
↓ Th1 response
↑ IL-4, IL-5, IL-13, IgE




↓ BCG, Cholera, Tetanus vaccines








↑ T cell activation, exhaustion and death
Antigen presentation





↓ Hepatitis B, Influenza, measles vaccines
↑ Influenza, PPV23 and PCV




e) Tuberculosis (TB) ↓ IFN-y, IL-1β, IL-18
in Active TB
↑ T reg in Active TB




↑ Tetanus toxoid, other antigens (151)
4. PZQ co-administration ↑ Antigen unmasking, recognition and
Antibody neutralization
↑ Antibody maturation, isotype switching
and Affinity maturation
↑ Specific IgE, IgA, IgG4, IgG2, and
eosinophils Effector T cell frequency
↑ Th2 IFN-y, IL-5, IL-4, and IL-13







↑ Sm28GST and measles vaccine,




↑, increased and ↓, decreased.
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FIGURE 1 | Schematic summary of PZQ-induced immune-modulatory responses that potentially impact vaccine response upon co-administration/delivery. PZQ acts
on parasite tegument causing vacuolation and blebbing. This unmasks worm antigens and elicits an increased antigen recognition, antibody reactivity, amplification
and affinity maturation, and alleviates the immune suppression induced by live parasites.
Previous studies have demonstrated PZQ-induced modulation
of cellular cytokine response to GST (23, 24). Likewise, more
subjects exhibit an increased Sh28GST specific cytokine with a
shift toward a more pro-inflammatory phenotype following PZQ
treatment than before treatment (23, 24). However, a definite
conclusion on the role of the PZQ treatment in the outcome of
this trial cannot be made. Preferably, next studies should include
a control arm whereby the timing of PZQ treatment is shifted
several weeks before or after the vaccine administration.
Indeed, PZQ treatment markedly alters both the polarization
and magnitude of schistosome specific cytokine responses with
longer-term immunological impact than just transient clearance
of infection. In the human host, Th2 biased response in form
of increased parasite-specific IgE, eosinophil numbers, soluble-
high and low affinity IgE receptors on eosinophils and CD23+B
cells following PZQ administration is observed (23, 171, 172),
which has been related to resistance to reinfection (172–
174). In addition, PZQ chemotherapy alleviates the immune
suppression induced by schistosomes by downregulating the
immune dampening T-reg, Th17 cell numbers and IL-10
cytokine levels (23, 24, 175, 176). Clearance of infection
following PZQ administration results in increased effector T
cell frequency, increased Schistosome-specific cytokine response
and decreased levels of T reg. This contrasts with the
immune suppressive profile during infection such as antigen
specific hypo-responsiveness, T cell memory pool distortion
and increased CD4+CD25+FOXP3+T cell numbers (177).
Consequently, in a randomized trial in Entebbe, Uganda,
PZQ treatment significantly, although transiently, improved
vaccine response to measles immunization in S. mansoni
infected pre-school children (169). Noteworthy, this effect
seems greatest when PZQ is administered a few weeks before
immunization (169).
In conclusion, although PZQ has been deemed to be non-
immunogenic in itself and thus have no impact on vaccine
efficacy, PZQ-induced antigenic release elicits both transient
and long term immune modulatory effects (23, 165, 175,
178) (Figure 1) which in turn, potentially augment or mask
vaccine responses. This is particularly important given that
future schistosome vaccine trials in endemic settings target
adult subjects, whose immunological and exposure profile has
been shaped by repeated exposures and or PZQ treatment. As
such PZQ-vaccine co-delivery could either be a very effective,
more wholistic strategy to enhance vaccine response and efficacy
or be detrimental to detecting vaccine efficacy in late-stage
clinical trials. Therefore, different vaccine schedules with PZQ
chemotherapy needs to be assessed in order to select the
most appropriate vaccine-PZQ combination and immunization-
chemotherapy treatment schedule before embarking on such
strategies in phase 3 studies.
OUTLOOK
Given the potentially complex interaction of the above
mentioned factors within the target population (43), the
appropriate selection of trial subjects in which confounders
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have been taken into account appropriately, has become a true
challenge to vaccine development and testing. Recognizing
the fact that large phase 3 efficacy trials will be performed in
a randomized fashion, most likely correcting for potential
unknown or unidentified confounders within the trial,
understanding or recognizing the potential of these factors
will ultimately be important for extrapolation of trial results and
implementation of any schistosome vaccine across sub-Sahara
Africa. Moreover, the phase 3 design will have to take into
account the treatment of co-infections in the context of already
existing MDA programmes.
Therefore, we argue that considerable investment should
be made during early phase clinical testing in an attempt
to understand and disentangle these confounders. As a start,
thorough screening of subjects for co-infections, chronic diseases
and physiological disorders should be done in order to identify
confounders in early-stage clinical trials, and enable appropriate
selection of trial populations with sufficient heterogeneity at a
later stage. The inclusion of several trial arms with different
population subsets (e.g., high vs. low pre-exposure) is helpful
to unravel the interaction between co-infections and vaccine
responses. For treatable co-infections, the effects of pre-treatment
such as PZQ, artemisinin and or albendazole administration
at the same time or prior to vaccination should be carefully
incorporated into trial designs especially from phase II trial stage.
Additionally, timing of treatment and vaccine administration
maybe a crucial determining factor for PZQ masking of or
synergy with vaccine response and efficacy. Understanding the
interplay between drug administration and vaccine responses will
prove to be essential for implementation of novel vaccines in
MDA settings. In the case of co-infections such as HIV/AIDS
(which can be treated but not eliminated), testing and exclusion
of sero-positive volunteers is the current practice in phase 1
trials. However, including seropositive individuals in phase II
and III trials should be promoted to ensure population-wide
implementation of the vaccine after registration.
In larger, late-stage stage clinical trials, the predominantly age
dependent distribution of infection intensity and development of
protective immunity among endemic populations (46) supports
the need for careful selection of analysis methods and tools
for handling trial data. Implementing approaches such as pre-
defined sub-group analysis, hierarchical clustering analysis and
stratified randomization with regards to age, and minimal and
intense prior exposure in trials is likely to be useful. This
would help to explicitly identify the immunologically distinct
heterogenous groups and give useful insights into differential
vaccine efficacy.
Controlled Human infection (CHI) models present an
opportunity to not only disentangle the different parameters
at play in endemic settings, but also accelerate the vaccine
development pipeline in general. In the implementation of
the CHI model, healthy volunteers are intentionally infected
with a pathogen with the aim of generating knowledge on
natural history of a disease, testing vaccines or therapeutics,
and developing reliable and defined models of infection
for future studies (179). These studies are controlled in
terms of dose and route, production and selection of the
pathogen strain administered. Additionally, a “controlled”
condition/environment is key to prevent natural infection during
the study period (179). Therefore, signs and symptoms of
disease, and evolution of responses following a defined timing
of the exposure can be observed in a well described and
managed manner. This makes it possible to study the natural
history of infection, host-pathogen interactions, evolution of
immune responses and provide a preliminary assessment of
vaccine efficacy (180, 181). The CHI models are also proof
of concept studies and furthermore enable identification of
correlates of protection. This approach allows for testing and
early selection of promising vaccine candidates in a smaller group
of healthy volunteers (<100), within a shorter period of time
under controlled conditions compared to the classical vaccine
testing methods (182). Hence, CHI studies reduce the burdening
cost and time requirements, and the high downstream vaccine
efficacy failure, associated with classical clinical trials approach.
Noteworthy, for safety and ethical concerns, the CHI approach is
applicable only for infections/diseases that are self-resolving and
or are treatable such as schistosomiasis (179, 180).
The recent development of a controlled Human Infection
model for Schistosomiasis (CHI-S), utilized single-sex cercariae
for infection of healthy Dutch volunteers (181). This approach
prevents the risk of egg-related pathologies as seen in the
“natural” mixed-sex schistosome infections, while preserving the
ability to cause infection and mature into adult schistosomes
in human subjects (183). The highly sensitive diagnostic test,
Circulating Anodic Antigen (CAA) test is used to detect infection
that usually occurs between 6 and 12 weeks after the CHI
procedure (181). Subjects are then treated with PZQ at 8 or
12 weeks post exposure to ensure clearance of infection (181).
The first CHI-S trial demonstrates that the male-only CHI-S
is safe and tolerable among naïve Dutch volunteers with about
82% infection rate, and absence of schistosome egg production
(181). Despite obvious limitations of the single-sex nature of the
CHI-S model, it can nevertheless be used as a screening tool
for future schistosomiasis vaccine candidates and new drugs.
More importantly, the implementation of the CHI-S model in
endemic settings provides a unique opportunity to disentangle
the aforementioned distinctive immune responses and potential
natural resistance, to Schistosoma infection and vaccines among
endemic populations (184). This would not only accelerate
vaccine development and testing but also help unravel the
heterogeneity in vaccine immunogenicity, safety, and efficacy.
CONCLUSION
The urgent need for a vaccine to eliminate the burden
of the schistosomiasis in LMICs calls for acceleration in
the testing and subsequent approval of the current vaccine
candidates. However, endemic populations exhibit a multiplicity
of distinctive disease transmission, exposure, pathogenesis,
genetic and environmental factors that result in immunological
challenges as summarized in Table 1. These potentially impact
vaccine responses and efficacy and amplify the chances of vaccine
failures. Therefore, significant consideration has to be conceded
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to these immunological challenges in order to accelerate vaccine
development and testing. Studies to investigate and accurately
establish the impact and extent to which these immunological
challenges affect host immune and vaccine response should
become a fundamental facet of baseline and or preparatory
studies as well the actual trial protocols for vaccine testing in
endemic settings.
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